Article(id=1329834985739104805, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329834929829031997, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.10.015, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1681228800000, receivedDateStr=2023-04-12, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794986967738, onlineDateStr=2026-11-18, pubDate=1696867200000, pubDateStr=2023-10-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794986967738, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794986967738, creator=13701087609, updateTime=1794986967738, updator=13701087609, issue=Issue{id=1329834929829031997, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='10', pageStart='1017', pageEnd='1132', issueExtLink='null', onlineDate='null', pubDate='1696867200000', pubDateStr='2023-10-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794986954409, creator='13701087609', updateTime=1794988028507, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329839435350389370, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329834929829031997, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329839435350389371, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329834929829031997, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1104, endPage=1109, ext={EN=ArticleExt(id=1329834987492323878, articleId=1329834985739104805, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on the efficacy of glucagon-like peptide-1 receptor agonists combined with basal insulin, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=
In recent years, the complex preparation of glucagon-like peptide-1 receptor agonist (GLP-1RA) and basal insulin has attracted much attention. It has significant efficacy and good safety in patients with type 2 diabetes mellitus, which can effectively control blood glucose level, reduce body mass gain, gastrointestinal adverse reactions and the risk of cardiovascular diseases, reduce the incidence of hypoglycemia and treatment costs, and improve patient compliance. This article reviewed the research progress of GLP-1RA and basic insulin compound preparation, to clarify its mechanism and efficacy, and provide certain reference for clinical practice.
, authors=Yanmei SU
1, Liping GU
2, *, authorsList=Yanmei SU, Liping GU, authorCompany=null, correspAuthors=Liping GU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329834987731399207, articleId=1329834985739104805, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=胰高血糖素样肽-1受体激动剂联合基础胰岛素疗效研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=
胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)与基础胰岛素的复合制剂是近年来关注的热点,其对2型糖尿病(type 2 diabetes mellitus)患者疗效显著且安全性良好,可有效控制血糖水平,减少体质量增加、胃肠道不良反应及心血管疾病的发生风险,降低低血糖(hypoglycemia)发生率及治疗成本,提高患者依从性。现对GLP-1RA和基础胰岛素复合制剂研究进展作一综述,旨在阐明其作用机理及疗效,为临床提供一定参考。
, authors=苏燕妹
1, 顾丽萍
2, *, authorsList=苏燕妹, 顾丽萍, authorCompany=null, correspAuthors=顾丽萍, authorNote=
, correspAuthorsNote=
顾丽萍,副主任医师,博士,研究方向:胰岛素抵抗相关疾病。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=H2DTd9vgNA0xcmQ7R8+01w==, magXml=9PV2pbwBeBFM7yzJP2Jy7g==, pdfUrl=null, pdf=eT4j01rCl8J9RNlfuda9Kw==, pdfFileSize=1542970, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=qkwyodWQLMiTiiliSqj2EQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329834988113080879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329834988217938481, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, authorId=1329834988113080879, language=EN, stringName=Yanmei SU, firstName=Yanmei, middleName=null, lastName=SU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329834988293435954, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, authorId=1329834988113080879, language=CN, stringName=苏燕妹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.上海交通大学医学院,上海 200025, bio={"content":"
苏燕妹,硕士研究生,研究方向:糖尿病相关疾病。
"}, bioImg=null, bioContent=
苏燕妹,硕士研究生,研究方向:糖尿病相关疾病。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329834987928531496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, xref=1., ext=[AuthorCompanyExt(id=1329834987932725801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834987928531496, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China), AuthorCompanyExt(id=1329834987941114410, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834987928531496, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.上海交通大学医学院,上海 200025)])]), Author(id=1329834988364739124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329834988444430902, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, authorId=1329834988364739124, language=EN, stringName=Liping GU, firstName=Liping, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, *, address=
2.Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329834988511539767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, authorId=1329834988364739124, language=CN, stringName=顾丽萍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, *, address=
2.上海交通大学医学院附属第一人民医院内分泌代谢科,上海 200080, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329834988020806187, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, xref=2., ext=[AuthorCompanyExt(id=1329834988025000492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834988020806187, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China), AuthorCompanyExt(id=1329834988033389101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834988020806187, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.上海交通大学医学院附属第一人民医院内分泌代谢科,上海 200080)])])], keywords=[Keyword(id=1329834988616397368, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, language=EN, orderNo=1, keyword=glucagon-like peptide-1 receptor agonist), Keyword(id=1329834988712866361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, language=EN, orderNo=2, keyword=insulin), Keyword(id=1329834988779975226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, language=EN, orderNo=3, keyword=compound preparation), Keyword(id=1329834988855472699, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, language=CN, orderNo=1, keyword=胰高血糖素样肽-1受体激动剂), Keyword(id=1329834988922581564, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, language=CN, orderNo=2, keyword=胰岛素), Keyword(id=1329834989002273341, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, language=CN, orderNo=3, keyword=复合制剂)], refs=[Reference(id=1329834989107130942, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Li Y, Teng D, Shi X,
et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. Br Med J, 2020, 369: m997., articleTitle=null, refAbstract=null), Reference(id=1329834989174239807, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Ji L, Hu D, Pan C,
et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J]. Am J Med, 2013, 126(10): e911-e922., articleTitle=null, refAbstract=null), Reference(id=1329834989245542976, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Harris S, Abrahamson MJ, Ceriello A,
et al. Clinical considerations when initiating and titrating insulin degludec/liraglutide (IDegLira) in people with type 2 diabetes[J]. Drugs, 2020, 80(2): 147-165., articleTitle=null, refAbstract=null), Reference(id=1329834989337817665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Tikhanovich I, Cox J, Weinman SA. Forkhead box class O transcription factors in liver function and disease[J]. J Gastroenterol Hepatol, 2013, 28(1): 125-131., articleTitle=null, refAbstract=null), Reference(id=1329834989417509442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=López-Jaramillo P, Gómez-Arbeláez D, López-López J,
et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes[J]. Horm Mol Biol Clin Investig, 2014, 18(1): 37-45., articleTitle=null, refAbstract=null), Reference(id=1329834989480424003, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaur G, Tee GH, Ariaratnam S,
et al. Depression, anxiety and stress symptoms among diabetics in Malaysia: a cross sectional study in an urban primary care setting[J]. Bio Med Central family practice, 2013, 14: 69., articleTitle=null, refAbstract=null), Reference(id=1329834989547532868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials[J]. Front Endocrinol (Lausanne), 2020, 11: 178., articleTitle=null, refAbstract=null), Reference(id=1329834989631418949, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019[J]. Diabetes Care, 2019, 42(Suppl 1): S90-S102., articleTitle=null, refAbstract=null), Reference(id=1329834989685944902, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Makimura H, Stanley TL, Suresh C,
et al. Metabolic effects of long-term reduction in free fatty acids with acipimox in obesity: a randomized trial[J]. J Clin Endocrinol Metab, 2016, 101(3): 1123-1133., articleTitle=null, refAbstract=null), Reference(id=1329834989748859463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu H, Luo B, Chen X,
et al. Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population[J]. J Diabetes Investig, 2022, 13(4): 652-656., articleTitle=null, refAbstract=null), Reference(id=1329834989811774024, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Inoue M, Lorenz M, Muto H,
et al. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (IGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: a phase Ⅰ randomized trial[J]. Diabetes Obes Metab, 2019; 21(8): 2001-2005., articleTitle=null, refAbstract=null), Reference(id=1329834989870494281, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Perreault L, Rodbard H, Valentine V,
et al. Optimizing fixed-ratio combination therapy in type 2 diabetes[J]. Adv Ther, 2019, 36(2): 265-277., articleTitle=null, refAbstract=null), Reference(id=1329834989929214538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Valentine V, Goldman J, Shubrook JH. Rationale for, initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes[J]. Diabetes Ther, 2017, 8(4): 739-752., articleTitle=null, refAbstract=null), Reference(id=1329834989992129099, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Yao-Borengasser A, Varma V, Bodles AM,
et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone[J]. J Clin Endocrinol Metab, 2007, 92(7): 2590-2597., articleTitle=null, refAbstract=null), Reference(id=1329834990063432268, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaneto H, Koshida R, Baxter M. Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: an innovative solution to a complex therapeutic challengee[J]. Diabetes Obes Metab, 2020, 22(Suppl 4): 24-34., articleTitle=null, refAbstract=null), Reference(id=1329834990130541133, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Dutta D, Khandelwal D, Kalra S. Injectable combination therapies for the management of diabetes: an Indian perspective[J]. Expert Opin Drug Metab Toxicol, 2020, 16(3): 209-216., articleTitle=null, refAbstract=null), Reference(id=1329834990185067086, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Gough SC, Bode B, Woo V,
et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes[J]. Lancet Diabetes Endocrinol, 2014, 2(11): 885-893., articleTitle=null, refAbstract=null), Reference(id=1329834991816651343, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Gough SC, Bode BW, Woo VC,
et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial[J]. Diabetes Obes Metab, 2015, 17(10): 965-973., articleTitle=null, refAbstract=null), Reference(id=1329834991908926032, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Rodbard HW, Bode BW, Harris SB,
et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with type 2 diabetes: the DUAL Ⅳtrial[J]. Diabet Med, 2017, 34(2): 189-196., articleTitle=null, refAbstract=null), Reference(id=1329834991971840593, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Harris SB, Kocsis G, Prager R,
et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL Ⅵ randomized clinical trial[J]. Diabetes Obes Metab, 2017, 19(6): 858-865., articleTitle=null, refAbstract=null), Reference(id=1329834992034755154, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Sesti G, Bardtrum L, Dagdelen S,
et al. A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/ml at 26 weeks: DUAL Ⅷ, a randomized trial designed to resemble clinical practice[J]. Diabetes Obes Metab, 2020, 22(5): 873-878., articleTitle=null, refAbstract=null), Reference(id=1329834992148001363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Philis-Tsimikas A, Billings LK, Busch R,
et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes[J]. Diabetes Obes Metab, 2019, 21(6): 1399-1408., articleTitle=null, refAbstract=null), Reference(id=1329834992210915924, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Buse JB, Vilsboll T, Thurman J,
et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)[J]. Diabetes Care, 2014, 37(11): 2926-2933., articleTitle=null, refAbstract=null), Reference(id=1329834992290607701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Lingvay I, Pérez Manghi F, García-Hernández P,
et al. Effect of insulin glargine up-titration
vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL Ⅴ randomized clinical trial[J]. J Am Med Assoc, 2016, 315(9): 898-907., articleTitle=null, refAbstract=null), Reference(id=1329834992349327958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Billings LK, Doshi A, Gouet D,
et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL Ⅶ randomized clinical trial[J]. Diabetes Care, 2018, 41(5): 1009-1016., articleTitle=null, refAbstract=null), Reference(id=1329834992420631127, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=El-Sayed MM, Ghareeb DA, Talat HA,
et al. High fat diet induced insulin resistance and elevated retinol binding protein 4 in female rats; treatment and protection with
Berberis vulgaris extract and vitamin A[J]. Pak J Pharm Sci, 2013, 26(6): 1189-1195., articleTitle=null, refAbstract=null), Reference(id=1329834992475157080, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Pei Y, Agner BR, Luo B,
et al. DUAL Ⅱ China: superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin[J]. Diabetes Obes Metab, 2021, 23(12): 2687-2696., articleTitle=null, refAbstract=null), Reference(id=1329834992546460249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaku K, Araki E, Tanizawa Y,
et al. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial[J]. Diabetes Obes Metab, 2019, 21(12): 2674-2683., articleTitle=null, refAbstract=null), Reference(id=1329834992613569114, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Janez A, Őrsy P, Stachlewska K,
et al. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: a post hoc analysis of the DUAL Ⅱ and DUAL Ⅸ trials[J]. Diabetes Obes Metab, 2020, 22(4): 658-668., articleTitle=null, refAbstract=null), Reference(id=1329834992676483675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Aroda VR, González-Galvez G, Grøn R,
et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL Ⅷ): a multicentre, open-label, phase 3b, randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(8): 596-605., articleTitle=null, refAbstract=null), Reference(id=1329834992739398236, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Kawaguchi Y, Miyamoto S, Hajika Y,
et al. Efficacy of IDegLira versus IDegAsp therapy in patients with type 2 diabetes: a randomized crossover study by isCGM[J]. Adv Ther, 2022, 39(6): 2688-2700., articleTitle=null, refAbstract=null), Reference(id=1329834992814895709, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Oe Y, Nomoto H, Nakamura A,
et al. Switching from insulin degludec plus dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide improves glycemic variability in patients with type 2 diabetes: a preliminary prospective observation study[J]. J Diabetes Res, 2022, 2022: 5603864., articleTitle=null, refAbstract=null), Reference(id=1329834992882004574, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=King AB, Philis-Tsimikas A, Kilpatrick ES,
et al. A fixed ratio combination of insulin degludec and liraglutide (IDegLira) reduces glycemic fluctuation and brings more patients with type 2 diabetes within blood glucose target ranges[J]. Diabetes Technol Ther, 2017, 19(4): 255-264., articleTitle=null, refAbstract=null), Reference(id=1329834992940724831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Rizza S, Piciucchi G, Mavilio M,
et al. Effect of deprescribing in elderly patients with type 2 diabetes: IDegLira might improve quality of life[J]. Biomed Pharmacother, 2021, 144: 112341., articleTitle=null, refAbstract=null), Reference(id=1329834993003639392, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Linjawi S, Bode BW, Chaykin LB,
et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL Ⅲ randomized clinical trial[J]. Diabetes Ther, 2017, 8(1): 101-114., articleTitle=null, refAbstract=null), Reference(id=1329834993066553953, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Saki F, Ashkani-Esfahani S, Karamizadeh Z. Investigation of the relationship between retinol binding protein 4, metabolic syndrome and insulin resistance in Iranian obese 5 - 17 year old children[J]. Iran J Pediatr, 2013, 23(4): 396-402., articleTitle=null, refAbstract=null), Reference(id=1329834993133662818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaneto H, Takami A, Spranger R,
et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (IGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: the LixiLan JP-L randomized clinical trial[J]. Diabetes Obes Metab, 2020, 22(Suppl 4): 3-13., articleTitle=null, refAbstract=null), Reference(id=1329834993204965987, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Price H, Blüher M, Prager R,
et al. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study[J]. Diabetes Obes Metab, 2018, 20(4): 954-962., articleTitle=null, refAbstract=null), Reference(id=1329834993276269156, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Warren M, Steel D. Clinical use of IDegLira: initiation to titration after basal insulin[J]. Clin Diabetes, 2020, 38(1): 62-70., articleTitle=null, refAbstract=null), Reference(id=1329834993355960933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Vilsbøll T, Blevins TC, Jodar E,
et al. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin[J]. Diabetes Obes Metab, 2019, 21(6): 1506-1512., articleTitle=null, refAbstract=null), Reference(id=1329834993435652710, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Marso SP, Daniels GH, Brown-Frandsen K,
et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322., articleTitle=null, refAbstract=null), Reference(id=1329834993506955879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Buse JB, Rosenstock J, Sesti G,
et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)[J]. Lancet, 2009, 374(9683): 39-47., articleTitle=null, refAbstract=null), Reference(id=1329834993590841960, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Shao H, Kianmehr H, Guo J,
et al. Efficacy of IGlarLixi on 5-year risk of diabetes-related complications: a simulation study[J]. J Diabetes Complications, 2022, 36(3): 108132., articleTitle=null, refAbstract=null), Reference(id=1329834993712476777, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Raya PM, Blasco FJA, Hunt B,
et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence[J]. Diabetes Obes Metab, 2019, 21(6): 1349-1356., articleTitle=null, refAbstract=null), Reference(id=1329834993817334378, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Norwood P, Chen R, Jaeckel E,
et al. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used[J]. Diabetes Obes Metab, 2017, 19(11): 1562-1569., articleTitle=null, refAbstract=null), Reference(id=1329834993901220460, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosenstock J, Aronson R, Grunberger G,
et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the lixilan-O randomized trial[J]. Diabetes Care, 2016, 39(11): 2026-2035., articleTitle=null, refAbstract=null), Reference(id=1329834993972523629, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Blonde L, Rosenstock J, Del Prato S,
et al. Switching to IGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the lixilan-G randomized clinical trial[J]. Diabetes Care, 2019, 42(11): 2108-2116., articleTitle=null, refAbstract=null), Reference(id=1329834994052215406, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Home PD, Aroda VR, Blonde L,
et al. Efficacy and safety of IGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison[J]. Diabetes Obes Metab, 2020, 22(11): 2170-2178., articleTitle=null, refAbstract=null), Reference(id=1329834994115129967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Yang W, Dong X, Li Q,
et al. Efficacy and safety benefits of IGlarLixi versus insulin glargine 100 U/ml or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: the LixiLan-O-AP randomized controlled trial[J]. Diabetes Obes Metab, 2022, 24(8): 1522-1533., articleTitle=null, refAbstract=null), Reference(id=1329834994270319216, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Rayner CK, Wu T, Aroda VR,
et al. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: a network meta-analysis[J]. Diabetes Obes Metab, 2021, 23(1): 136-146., articleTitle=null, refAbstract=null), Reference(id=1329834994341622385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Cannon AJ, Bargiota A, Billings L,
et al. Evaluation of the short-term cost-effectiveness of IDegLira versus basal insulin and basal-bolus therapy in patients with type 2 diabetes based on attainment of clinically relevant treatment targets[J]. J Manag Care Spec Pharm, 2020, 26(2): 143-153., articleTitle=null, refAbstract=null), Reference(id=1329834994404536946, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=McCrimmon RJ, Falla E, Sha JZ,
et al. Cost-effectiveness of IGlarLixi in people with type 2 diabetes mellitus suboptimally controlled on basal insulin plus metformin in the UK[J]. Diabetes Ther, 2021, 12(12): 3217-3230., articleTitle=null, refAbstract=null), Reference(id=1329834994459062899, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Dempsey M, Mocarski M, Langer J,
et al. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US[J]. J Med Econ, 2018, 21(11): 1110-1118., articleTitle=null, refAbstract=null), Reference(id=1329834994513588852, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Persano M, Nollino L, Sambataro M,
et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy[J]. Eur Rev Med Pharmacol Sci, 2021, 25(2): 923-931., articleTitle=null, refAbstract=null), Reference(id=1329834994580697717, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=Miller E, Doshi A, Grøn R,
et al. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy[J]. Diabetes Obes Metab, 2019, 21(12): 2643-2650., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329834987928531496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, xref=1., ext=[AuthorCompanyExt(id=1329834987932725801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834987928531496, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China), AuthorCompanyExt(id=1329834987941114410, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834987928531496, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.上海交通大学医学院,上海 200025)]), AuthorCompany(id=1329834988020806187, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, xref=2., ext=[AuthorCompanyExt(id=1329834988025000492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834988020806187, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China), AuthorCompanyExt(id=1329834988033389101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329834985739104805, companyId=1329834988020806187, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.上海交通大学医学院附属第一人民医院内分泌代谢科,上海 200080)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.10.015, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.10.015, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.10.015, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.10.015, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1696867200000, fullTextJson=null, articleText=null, reference=null)